However, PD1/PD-L1 inhibitors have also shown to be beneficial for TPS<50% EGFR-wildtype NSCLC, as combination therapy, or used as a later-line treatment8 and in an adjuvant setting. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.